{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:41:53Z","timestamp":1777902113255,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Science Progress"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Tachycardia is common in pediatric intensive care and may contribute to hemodynamic instability when persistent despite adequate resuscitation. Data on \u03b2-blocker therapy in critically ill children are limited. Our objective was to evaluate the safety and hemodynamic effects of propranolol in critically ill pediatric patients with persistent sinus tachycardia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective cohort study of children aged 1 month to 18 years who received propranolol in a tertiary-care pediatric intensive care unit between March 1, 2019, and March 1, 2024. The inclusion criteria were heart rate \u22652 standard deviations above age norms that persisted despite adequate resuscitation and conventional treatments. Patients with primary cardiac disease or a history of \u03b2-blocker use were excluded. Propranolol was administered orally or via a nasogastric tube at a dose of 1 mg\/kg\/day for persistent sinus tachycardia despite normothermia, adequate sedation-analgesia, and standard hemodynamic support. The primary outcome was the change in heart rate over 48 h. Secondary outcomes included trends in blood pressure, lactate and glucose levels, vasoactive\u2013inotropic score (VIS), and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 93 patients (median age, 19 months), propranolol caused a significant reduction in heart rate within 6 h (mean decrease, \u223c30 bpm;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with stabilization by 24 h. Systolic (SBP) and diastolic blood pressures (DBP) increased modestly (SBP +7 mmHg; DBP +3 mmHg,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and lactate levels declined significantly at 6 h (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.003). The VIS did not change significantly. Adverse events were rare (hypotension 2.2%, bradycardia 1.1%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large pediatric cohort, propranolol was well tolerated and linked to positive hemodynamic and metabolic effects. These results support cautious use in carefully selected critically ill children and emphasize the need for future prospective trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00368504261424393","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:55:43Z","timestamp":1771340143000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beta-blocker therapy in pediatric intensive care: Safety and efficacy of propranolol for persistent tachycardia"],"prefix":"10.1177","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-2260","authenticated-orcid":false,"given":"Emrullah","family":"Ayg\u00fcler","sequence":"first","affiliation":[{"name":"Istanbul University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5264-3038","authenticated-orcid":false,"given":"Servet","family":"Y\u00fcce","sequence":"additional","affiliation":[{"name":"Department of Public Health, Istanbul Provincial Health Directorate, Istanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8818-3088","authenticated-orcid":false,"given":"Muhammed","family":"Susuz","sequence":"additional","affiliation":[{"name":"Istanbul University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-3629","authenticated-orcid":false,"given":"Beste","family":"G\u00fcnebakan","sequence":"additional","affiliation":[{"name":"Istanbul University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9578-9267","authenticated-orcid":false,"given":"Demet","family":"Demirkol","sequence":"additional","affiliation":[{"name":"Istanbul University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-012-2531-2"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm074"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001166"},{"key":"e_1_3_3_5_2","first-page":"46","article-title":"Application of beta-blockers in burn management","volume":"35","author":"Kopel J","year":"2022","unstructured":"Kopel J, Brower GL, Sorensen G, et al. Application of beta-blockers in burn management. Proc (Bayl Univ Med Cent) 2022; 35: 46\u201350.","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2015.08.015"},{"key":"e_1_3_3_7_2","first-page":"79","volume-title":"A practical handbook on pediatric cardiac intensive care therapy","author":"Klauwer D","year":"2018","unstructured":"Klauwer D, Neuhaeuser C. Cardiovascular monitoring and cardiovascular drug therapy. In: A practical handbook on pediatric cardiac intensive care therapy. Cham, Switzerland: Springer, 2018, pp.79\u2013101."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e318031afd3"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2020.09.117"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199605000-00004"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31828a2bbd"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005357"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05878-6"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.85.2.790"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.22.2210"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.20134"},{"key":"e_1_3_3_17_2","article-title":"Part 14: pediatric advanced life support","volume":"122","author":"Pals BCD","year":"2010","unstructured":"Pals BCD. Part 14: pediatric advanced life support. Circulation 2010; 122: S876\u2013S908.","journal-title":"Circulation"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000150028.64264.14"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181c03dfa"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001078"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1580-2"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318265427e"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0b013e318166d414"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jbcr\/iry014"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2098376"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2025.111824"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.278477"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1448573"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-5153.2009.00323.x"}],"container-title":["Science Progress"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00368504261424393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00368504261424393","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00368504261424393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:20:07Z","timestamp":1777634407000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00368504261424393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/00368504261424393"],"URL":"https:\/\/doi.org\/10.1177\/00368504261424393","relation":{},"ISSN":["0036-8504","2047-7163"],"issn-type":[{"value":"0036-8504","type":"print"},{"value":"2047-7163","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"00368504261424393"}}